DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm
March 26, 2021 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 23, 2021 09:00 ET
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 22, 2021 21:00 ET
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 22, 2021 08:30 ET
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, iRhythm Technologies, Tyson Foods, and Clover Health Investments and Encourages Investors to Contact the Firm
March 17, 2021 15:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 17, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Global Cancer CDK Inhibitor Market 2019-2029 - Pipeline Analysis is estimated to be US$ 16.1 billion by 2030 with a CAGR of 10.4% during the forecast period - by PMI
March 17, 2021 11:35 ET
|
PMI
Covina CA, March 17, 2021 (GLOBE NEWSWIRE) -- The Global Cancer CDK Inhibitor Market accounted for US$ 6.0 billion in 2019 and is estimated to be US$ 16.1 billion by 2029 and is anticipated to...
BrightInsight and AstraZeneca Collaborate to Enhance Disease Management
March 16, 2021 08:30 ET
|
BrightInsight
SAN JOSE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global regulated digital health platform for biopharma and medtech, announced today the launch of...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, iRhythm Technologies, Tyson Foods, and Clover Health Investments and Encourages Investors to Contact the Firm
March 10, 2021 17:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against 9F, AstraZeneca, iRhythm Technologies, and Tyson Foods and Encourages Investors to Contact the Firm
March 03, 2021 17:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bit Digital, CleanSpark, 9F, Inc., and AstraZeneca and Encourages Investors to Contact the Firm
February 24, 2021 18:00 ET
|
Bragar Eagel & Squire
NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...